Table 3.

ELISA results for patients and controls from the United States and Denmarka

Type of resultCDUCControl
SurgicalOutpatientSurgicalOutpatientSurgicalHealthy
USDKUSDKUSDKUSDKUSDKUSDK
No. tested29471137234253174172819579
No. positive (s/p >0.312)6313800191254
% positive20.76.411.511.10.00.03.212.25.97.12.65.1
  • a Abbreviations: US, United States; DK, Denmark. For all comparisons of surgical to matched outpatient group, no significant differences were found. Significance: among U.S. groups, CD versus controls, P = 0.0002; OR = 2.03 (1.57–2.64); UC versus controls, P = 1.00; OR = 0.60 (0.09–3.75); CD versus UC, P = 0.005; OR = 1.44 (1.25–1.69); among Denmark groups, no significant differences; among U.S. and Denmark combined groups, CD versus controls, P = 0.0006; OR = 3.32 (1.66–6.63); UC versus controls, P = 0.26; OR = 1.66 (0.70–3.93); CD versus UC, P = 0.089; OR = 2.00 (0.95–4.21); IBD versus controls, P = 0.003; OR = 2.66 (1.37–5.16). Fisher's exact test, two sided, was used (95% confidence interval). The number tested was less than total number in study for some groups due to failure to acquire samples. The positive rates by group, shown as number positive/total number (percent), are 30/261 (11.5), 10/164 (6.1), and 12/319 (3.8) for CD, UC, and control groups, respectively. The positive rate overall for all IBD patients (CD plus UC) was 40 positive of 425 total (9.4%). Combined positive percents (United States plus Denmark) were 11.8, 11.4, 0, 9.5, 6.7, and 3.3 for CD, UC, and control surgical and outpatient groups, respectively.